+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Early Phase 1
Age: 18Years - 70Years
All Genders
ID05539833

Study of KSH01-TCR-T Cell Therapy for Adults with Refractory or Recurrent Solid Tumors A Single-Arm Clinical Trial Evaluating Safety and Tumor Response

Led by TCRx Therapeutics Co.Ltd · Updated on 2026-10-23

50

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the safety and effectiveness of KSH01-TCR-T cell therapy in adults with refractory or relapsed solid tumors. The study aims to observe how these TCR-T cells activate and multiply in patients and to assess their impact on tumor size and survival. This early phase 1 trial focuses on patients whose tumors express specific targets and who have limited treatment options due to treatment failure or intolerance. Participants receive an injection of KSH01-TCR-T cells, which are engineered immune cells designed to target cancer cells specifically. The study includes a dose escalation phase for patients without standard treatment options and a dose expansion phase for those whose tumors progressed after first-line therapy. The treatment is administered once the cells are prepared from the participants own immune cells and meet quality standards. During the study, participants will be closely monitored for treatment-related side effects and changes in tumor size for about two years. Researchers will also study the drugs behavior in the body, immune responses, biomarkers, and maximum tolerated dose over this period, with some measures extending up to five years. Participants will undergo various assessments, including tumor biopsies, blood tests, and physical evaluations, to evaluate the therapys effects and safety throughout the study.

CONDITIONS

Brief Title

KSH01-TCRT Solid Tumors

Research Team

J

JingChao Liu

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here